Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 13/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.43 |
| ▸ | RHEB | Q15382 | 3/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999997 | 0.83 | SOS1 (0.46) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL5999724 | 0.82 | HTR2A (0.67) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5998632 | 0.81 | NOS1 (0.51) | HTR2ATRPM8SLC6A4KCNH2 | |
| SCHEMBL5998731 | 0.80 | PTGS1 (0.48) | HTR2ATRPM8 | |
| SCHEMBL5999978 | 0.77 | HTR2A (0.53) | HTR2ATRPM8SLC6A4KCNH2 | |
| SCHEMBL6000287 | 0.75 | RHEB (0.66) | HTR2ATRPM8SLC6A4KCNH2RHEB | |
| SCHEMBL6000147 | 0.74 | HTR2A (0.43) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL3483906 | 0.72 | AHR (0.44) | AHRF7LTA4HF3NR4A2 | |
| SCHEMBL6000189 | 0.71 | HTR2A (0.40) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5497556 | 0.71 | HTR2A (0.41) | HTR2ATRPM8SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | AHR 192/4885F7 2717/4885LTA4H 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.